1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Digital Landscape: Asthma

Digital Landscape: Asthma

  • October 2018
  • 162 pages
  • ID: 5588785
In this report:
WITH PEAKS SEEN IN JUNE AND NOVEMBER 2017 AT ~##K VISTS EACH SIGNIFICANT INCREASE IN PAID KEYWORDS WAS DETECTED IN OCTOBER 2017 (~##.##K VS. ~## / MONTH SINCE LAUNCH), IN LINE WITH THE APPROVAL OF FASENRA IN NOVEMBER THE SITE WAS SUPPORTED BY A MONTHLY AVERAGE OF ~##.##K PAID KEYWORDS IN Q## 2017; TOP PAID KEYWORDS 'NEUTROPHILS' AND 'EOSINOPHILS' EACH ACCOUNTED FOR ~##% OF TRAFFIC TO THE SITE

Summary

Table of Contents

Search Inside

Digital Landscape: Asthma

Brief

"Digital Landscape: Asthma", examines digital activities undertaken by pharma industry in support of therapies for asthma.

- The market research includes digital activities directed towards patients and/or HCPs.

- The geographic scope of the report is the United States, EUCAN(Canada (CA) and the 5EU countries - UK, Germany (DE), France (FR), Italy (IT) & Spain (ES)).

- The industry report covers both inhaled and injectable asthma therapies.

Key Findings

- US Patients: Strong feature-rich branded sites for both inhaled and injectable asthma therapies in the US. Most 2017 activity seen in the injectable therapy space, with the launch of branded and unbranded sites by AstraZeneca following approval of Fasenra, as well as activity from other companies with existing severe / allergic asthma therapies. Overall, the pharma-sponsored social media and mobile app landscapes for US patients are underdeveloped.

- US HCPs: Good brand support available for US HCPs in the asthma space from AstraZeneca, Teva and GSK. All additional branded activity in 2017 was in the injectable space following approval of AstraZeneca's Fasenra. Unbranded landscape is sparse with sites only detected for severe asthma from AstraZeneca and Sanofi / Regeneron. Social media activity is limited to corporate accounts and examples of good quality, pharma-sponsored mobile apps are lacking.

- EUCAN Patients: Most companies have brand sites for EUCAN patients, primarily in Germany and the UK. Good examples of single-country unbranded asthma initiatives exist. Opportunity to develop multi-country, local-language campaigns integrated with social media to provide a sense of community to asthma patients. Good quality, country-specific mobile apps available for EUCAN patients. Activity seen in the clever inhaler space from AstraZeneca and Teva.

- EUCAN HCPs: Boehringer Ingelheim affords the strongest branded and unbranded support for HCPs in EUCAN, and had the only additional activity in 2017. Limited social media support available, with Chiesi providing the best example of a respiratory-focused social media page for HCPs. Pharma mobile app landscape is relatively active, particularly in Spain, with a focus on disease and inhaler information.

Companies Mentioned: AstraZeneca, GSK, Boehringer Ingelheim, Teva, Novartis, Genentech, Merck, Sunovion, Chiesi, Sanofi Genzyme / Regeneron, Takeda, Sandoz / Hexal, Zambon, Orion, Mundipharma / Napp, Mylan, Meda, Astellas, Elpen.

Overview

- This business report examines digital activities undertaken by pharma in support of therapies for asthma.

- The study covers both inhaled and injectable asthma therapies.

- The analysis includes digital activities directed towards patients and/or HCPs, containing branded websites, unbranded disease awareness initiatives, social media and mobile apps.

- The market research is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also comprises analysis of data licensed from third parties e.g. website traffic, search engine optimization, digital display advertising, mobile app downloads, and social media interaction.

- The geographic scope of the report is the United States, Canada (CA) and the 5EU (UK, Germany (DE), France (FR), Italy (IT) & Spain (ES)), with EUCAN used as an abbreviation for Europe (EU) and Canada (CA) throughout.

- This industry report includes the research period from January 2017 - December 2017.

Great reasons to purchase

- Our Digital Landscape report offers an analysis of pharma multichannel activity in the digital asthma space, and can assist our pharma clients derive value in a number of ways:

- Competitive Intelligence: Track and compare main competitor activity across channels and distinguish top trends in asthma

- Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and analyze possibilities for novel digital campaigns

- Support additional brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess plausible gaps and alternatives for pipeline brands

- Business Development & Licensing: Assess topics and forecasts shaping digital health in asthma and beyond, and learn about main patient and physician online activities in asthma.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Nicolas helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Acute Asthma Global Clinical Trials Review, H2, 2018

Acute Asthma Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Acute Asthma Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Acute Asthma Global Clinical Trials Review, H2, 2018" provides an overview of Acute Asthma clinical trials ...

Asthma - Pipeline Review, H2 2018

Asthma - Pipeline Review, H2 2018

  • $ 2500
  • October 2018

Asthma - Pipeline Review, H2 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H2 2018, provides an overview of the Asthma (Respiratory) ...

Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2018

Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Adult Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2018" provides ...


ref:plp2018

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on